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Immune responseGoatpox, caused by goatpox virus (GTPV), is an acute feverish and contagious disease in goats often
associated with high morbidity and high mortality. To resolve potential safety risks and vaccination side
effects of existing live attenuated goatpox vaccine (AV41), two Semliki forest virus (SFV) replicon-based
bicistronic expression DNA vaccines (pCSm-AAL and pCSm-BAA) which encode GTPV structural proteins
corresponding to the Vaccinia virus proteins A27, L1, A33, and B5, respectively, were constructed. Then, theirs
ability to induce humoral and cellular response in mice and goats, and protect goats against virulent virus
challenge were evaluated. The results showed that, vaccination with pCSm-AAL and pCSm-BAA in
combination could elicit strong humoral and cellular responses in mice and goats, provide partial protection
against viral challenge in goats, and reduce disease symptoms. Additionally, priming vaccination with the
above-mentioned DNA vaccines could signiﬁcantly reduce the goats' side reactions from boosting
vaccinations with current live vaccine (AV41), which include skin lesions at the inoculation site and fevers.
Data obtained in this study could not only facilitate improvement of the current goatpox vaccination strategy,
but also provide valuable guidance to suitable candidates for evaluation and development of orthopoxvirus
vaccines.© 2009 Elsevier Inc. All rights reserved.Introduction
Goatpox, caused by goatpox virus (GTPV) belonging to the genus
Capripoxvirinae in the family Poxviridae, is an acute feverish and
contagious disease in goats. This disease is characterized by fever,
generalized skin nodules, lesions in the respiratory and gastrointest-
inal tracts, and lymph node enlargement (Kitching, 2004; Kitching
and Carn, 2004). GTPV has a genome of approximately 149 kbp
typically encoding more than 140 proteins. Similar to Orthopoxviruses,
maturation of GTPV during the viral life cycle results in two major
infectious forms of virus, intracellular mature virus particles (IMV)
and extracellular enveloped virus particles (EEV), which have
different repertoires of viral envelope proteins (Moss, 2001, 2006).
GTPV is endemic in Africa north of the Equator, theMiddle East, the
Indian subcontinent, and parts of the People's Republic of China. As the
most serious poxvirus disease of production animals, goatpox causes
highmortality and signiﬁcant economic losses, thereby posing amajor
obstacle to international trade. Accordingly, goatpox is categorized as a
notiﬁable disease by the World Organization for Animal Health (OIE)in), gx_liuqi@yahoo.com.cn
ll rights reserved.(Kitching, 2004; Kitching and Carn, 2004; Bowden et al., 2008). Both
live attenuated and inactivated vaccines are available in the preven-
tion and control of goatpox. Inactivated vaccines provide only short-
term immunity. Although highly immunogenic and longer term
immunoprotection is offered by live attenuated vaccines, some issues
remain to be solved, including risk of virulence reversion, and
difﬁculty in distinguishing vaccinated animals from infected ones.
Therefore, the use of live virus vaccines in nonendemic countries may
not be desirable (Kitching, 2003; Bowden et al., 2008).
The Kenyan vaccine strain of sheeppox virus and GTPV is used most
widely in the world, originally isolated from a sheep, and is possibly
related to lumpy skin disease virus (Kitching et al., 1987). Majority of
sheep and goats vaccinated with the Kenyan isolate developed neither
detectable anti-capripoxvirus antibodies nor clinical disease symp-
toms associated with capripoxvirus infection. However, they were
protected from subsequent infection from other capripoxviruses
(Babiuk et al., 2009). GTPV-AV41, the live attenuated GTPV vaccine
strain used widely in China, also has good immunogenicity. Recently,
however, increasing reports have shown that it may cause dangerous
complications, including generalized skin nodules and misbirth in
native breed goats in southern China, imported pure breeds, and
outbreds (Huang and Wei, 2004; Li et al., 2005; Zhao et al., 2005).
Accordingly, it is necessary to develop a safer and more effective
34 M. Zheng et al. / Virology 391 (2009) 33–43alternative approach to improve the current goatpox vaccination
strategy.
One strategy to reduce virus-associated complications is not to
vaccinate with the whole live virus, but instead with components of
the virus known to induce protective immunity. Several Vaccinia virus
(VACV) IMV envelope proteins have been identiﬁed as targets of
neutralizing antibodies, including A27, L1, H3, and D8 proteins (Davies
et al., 2005; Hsiao et al., 1999; Ichihashi and Oie, 1996; Lin et al., 2000;
Rodriguez et al., 1985; Wolffe et al., 1995). Furthermore, antibodies
against B5 protein neutralize EEVs (Bell et al., 2004), and antibodies
against A33 are protective in vivo even though they do not elicit
neutralizing antibodies (Galmiche et al., 1999). Both DNA and
recombinant protein vaccines using these individual outer membrane
proteins of vaccinia virus elicited protective antibody responses in
mouse and non-human primate models (Fogg et al., 2004; Hooper et
al., 2004). Moreover, polyvalent formulations with various combina-
tions of the four poxvirus antigens (A27, L1, B5, and A33) achieved
better protection than a monovalent formulation using only one of
these antigens (Hooper et al., 2003, 2004, Fogg et al., 2004).
The purpose of this work is to investigate the effectiveness of Semliki
forest virus (SFV) replicon-based DNA vaccines as novel, non-transmis-
sible GTPV vaccines. The results show that immunization in combination
with two DNA vaccines comprising A27, L1, A33, and B5 GTPV
homologues could elicit immunized mice and goats to produce speciﬁc
humoral and cellular responses. This not only providedpartial protection
against lethalGTPV challenge andreduced the severity of disease lesions,
but also signiﬁcantly reduced pathogenicity of the live attenuated
vaccine GTPV-AV41 in goats without affecting their immunogenicity.
Results
Construction and determination of the expression vector pCSm
An 8.0-kb fragment containing the replicon encoding regions and a
26S promoter of SFV was inserted into the EcoRV–SpeI site of
pIRESneo1, and the expression plasmid pCSm was obtained after
another 0.27-kb SmaI–EcoRV fragment was subsequently inserted to
supplement the ﬁrst part of the SFV genome (Fig. 1). To determine the
expression activity of pCSm, the EGFP gene was inserted into pCSm
and pCS. The resulting plasmids, pCSm-EGFP and pCS-EGFP, were then
transfected into BHK-21 cells using Lipofectamine 2000 reagent. After
incubation at 37 °C for 48 h, cells were observed under a ﬂuorescence
microscope. Results showed that pCSm-EGFP transfected cells could
express green ﬂuorescent protein, and the numbers of positive
expressing cells and expression amounts in pCSm-EGFP transfected
cells were approximately 10-fold higher than those in pCS-EGFP
transfected cells (Supplement Fig. 1).
Cloning of GTPV genes and construction of expression plasmids
Using the primer pairs listed in Table 1, the GTPVA27L, L1R, A33R, and
B5R orthologous genes from GTPV-AV41 were PCR ampliﬁed andFig. 1. Schematic demonstrations of expression vector of pCSm, pCSm-AAL and pCSm-BAA
nonstructural proteins 1–4 of Semliki forest virus (SFV); P26S: SFV 26S promoter; polyA: bovin
mouth disease virus (FMDV) O/NY00.sequenced, and the resulting sequences were submitted to Genbank
(accession number: EU024477–EU024480). These genes were subse-
quently cloned into expressionplasmid pCSm to create constructs pCSm-
A27, pCSm-L1, pCSm-A33, and pCSm-B5. A27L and B5R were linked in
frame with L1R and A33R using a FMDV 2A short peptide coding
sequence togenerate the twoexpressioncassettesA27L-2A-L1RandB5R-
2A-A33R, respectively. Further, the two bicistronic expression plasmids
pCSm-AAL and pCSm-BAAwere obtained (Fig. 1, Supplement Fig. 2).
Western blot analysis was performed to evaluate the expression
products. The predicted 17 kDa, 27 kDa, 22 kDa, and 26 kDa proteins
were expressed in pCSm-A27, pCSm-L1, pCSm-A33, and pCSm-B5
transfecting cells, respectively (Fig. 2). In addition to 17 kDa and
27 kDa, a 45-kDa protein band was observed in the pCSm-AAL
expression product (Fig. 2). It was presumed to be the un-cleavaged
polyprotein of A27-2A-L1. Similarly, an additional 49-kDa band
(putative polyprotein of B5-2A-A33) was also observed in the
pCSm-BAA expression product (Fig. 2).
Speciﬁc reaction antibodies
To determine the immunogenicity of the expression products,
groups of ten mice each were vaccinated intramuscularly with the
above-mentioned six DNA plasmids constructs, respectively (Experi-
ment 1). The mice were vaccinated at days 0 and 21. As a positive
control, ten mice were vaccinated intramuscularly with GTPV-AV41.
Sera were collected weekly after vaccination, and an equal volume of
sera from individual mice from the same groups was mixed and tested
for the presence of antibodies against GTPV, A27, A33, or B5.
As shown in Fig. 3A and Table 1, speciﬁc antibody titers of
recombinant plasmids and virus vaccinated mice increased dramati-
cally on DPI 7, and continued to increase after the boost. On DPI 35,
GTPV-speciﬁc and A27-speciﬁc antibody titers of pCSm-AAL and
pCSm-AAL+pCSm-BAA vaccinated mice were as high as or 2-fold
higher than those of virus vaccinated mice (12,800:12,800 and
12,800:6400, respectively), as measured by GTPV-infected-cell-lysate
or A27-speciﬁc ELISA. Moreover, A33-speciﬁc and B5-speciﬁc anti-
body titers of pCSm-BAA and pCSm-AAL+pCSm-BAAvaccinatedmice
were 8-fold higher than those of virus vaccinated mice (12,800:1600),
measured by A33-speciﬁc or B5-speciﬁc ELISA.
Further, two groups of four goats each were inoculated intramuscu-
larlywith pCSm-AAL+pCSm-BAA (Experiment 2). OnDPI 21, one group
was boostedwith the samedose; the other group and another four goats
were injected intradermally with GTPV-AV41. Sera were also collected
weeklyand tested for speciﬁc antibodies. Similarly, goats inoculatedwith
DNAvaccine developed speciﬁc antibodies on DPI 7, and these increased
after the boost (Fig. 3B). On DPI 42, GTPV-speciﬁc antibody titers of the
DNA+virus and virus vaccinated group were highest (25,600, Table 2),
andwere2-foldhigher than those of theDNAvaccinatedgroup (12,800);
however, A27-, A33-, and B5-speciﬁc antibody titers of the virus
vaccinated group were lower than those of the DNA and rDNA/virus
vaccinated groups (6400:25,600:12,800, 6400:25,600:12,800, and
6400:12,800:12,800, respectively). Interestingly, compared to the DNA. PCMV: human cytomegalovirus (CMV) immediate-early promoter/enhancer; nsP1–4:
e growth hormone poly A signal; 2A: coding sequence of 2A gene derived from foot-and-
Table 1
Speciﬁc reaction antibodies and neutralizing antibodies in mice sera.
Groups Speciﬁc reaction antibody titers
at DPI 35
Neutralizing
antibody
GTPV A27 A33 B5 DPI 14 DPI 35
pCSm-A27 6400 12,800 16 22
pCSm-L1 12,800 20 25
pCSm-A33 1600 25,600 10 16
pCSm-B5 1600 25,600 8 12
pCSm-AAL 12,800 12,800 16 25
pCSm-BAA 3200 12,800 12,800 11 16
pCSm-AAL+pCSm-BAA 12,800 12,800 12,800 12,800 23 35
GTPV-AV41 12,800 6400 1600 1600 20 32
pCSm ≤50 ≤50 ≤50 ≤50 ≤6 ≤6
Equal volume of sera from individual mice from the same groups was mixed and tested
for the presence of speciﬁc reaction antibodies against GTPV, A27, A33, or B5 by I-ELISA,
and neutralizing antibodies against GTPV by using a modiﬁed neutralization assay
based on observation of green ﬂuorescent protein.
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group were postponed at least 1 week directly after the boosting
vaccination; however, its titers still met or exceeded the level of the virus
vaccinated group on DPI 42 (Fig. 3B).
GTPV-speciﬁc neutralizing antibody responses
GTPV-speciﬁc neutralizing antibodies in sera from mice and goats
were measured by a modiﬁed neutralization assay based on observa-
tion of green ﬂuorescent protein using the EGFP expressing recombi-
nant GTPV, vTK-EGFP.
Paralleling that of the ELISA antibodies, mice vaccinated with
recombinant plasmids or viruses developed neutralizing responses on
DPI 14, and continuously increased after boosting. On DPI 35, GTPV-
speciﬁc neutralizing antibody titers of pCSm-AAL+pCSm-BAA and virus
vaccinated mice were highest (35 and 32); followed by those of pCSm-
A27, pCSm-L1, andpCSm-A27+pCSm-L1 (range 22–25). Those of pCSm-
A33, pCSM-B5, and pCSm-A33+pCSM-B5 were lowest (range 12–16).
Similarly, goats vaccinatedwith DNAvaccine developed neutralizing
antibodies on DPI 14, and these increased after the boost. As shown in
Table 2 and Supplement Fig. 3, on DPI 42, neutralizing antibody titers of
DNA+virus vaccinated group (mean=50.5) were higher than those of
the virus group (mean=43.3) and the DNA group (mean=38.3).
Speciﬁc T-lymphocyte proliferation responses
Speciﬁc T-lymphocyte proliferation responses of mice and goats
were measured by MTT assay. SI values higher than 1.5 indicated a
positive response. As shown in Fig. 4, except for the SI mean of pCSm-Fig. 2.Western blot analysis of expression products in BHK-21 cells transfected with recombi
3: pCSm-A27; lane 4: pCSm-L1; lane 5: pCSm-A33; lane 6: pCSm-B5; lane 7: pCSm-AAL; laB5 individually vaccinated mice had values lower than 1.5 when
simulated with GTPV-infected-cell-lysate, mice and goats vaccinated
with other DNA vaccines or virus all developed GTPV-speciﬁc
(simulated with GTPV-infected-cell-lysate) and protein-speciﬁc
(simulated with individual recombinant protein) T-lymphocyte
proliferation responses (SI mean ranges of mice and goats were
1.53–3.29 and 2.11–3.60, respectively). The highest SI value was
observed in samples from both mice and goats simulated with A33
protein. Analysis of each individual antigen-speciﬁc T-lymphocyte
proliferation response of mice showed no difference (PN0.05)
between the pCSm-AAL+pCSm-BAA group and all other individual
DNA vaccinated groups. Moreover, each individual antigen-speciﬁc T-
lymphocyte proliferation response of goats vaccinated with DNA
vaccine was lower (Pb0.01) than those of the virus group, whereas
those of the rDNA/virus group met (PN0.05) those of the virus group.
Speciﬁc IFN-γ responses in mice
On DPI 35, antigen-speciﬁc IFN-γ responses of mice were tested by
IFN-γ ELISPOT using GTPV-infected-cell-lysate or recombinant proteins
as a simulator, respectively. As shown in Fig. 5, mice vaccinated with
DNA vaccines or virus all developed antigen-speciﬁc IFN-γ responses
(mean positive dots range: 32–247). And except for those simulated
with the GTPV-infected-cell-lysate, IFN-γ producing cell numbers of the
pCSm-AAL+pCSm-BAA group met (PN0.05) or exceeded those of the
virus group and the individual DNA vaccine vaccinated group.
DNA prime vaccination alleviated side reaction of live virus vaccination
On DPI 21, group of goats pre-injected with pCSm-AAL+pCSm-BAA
(group 2.2) or PBS (group 2.3), were inoculated intradermally with
GTPV-AV41 and observed for clinical signs of side reactions. As shown in
Figs. 6, 7 and Table 3, from3days post virus inoculation, four goats in the
PBS/virus group developed apparent skin lesions with diameters of 1–
2 cm at the site of inoculation, and fevers with a mean highest
temperature of 39.9±0.4 °C (2/4 temperatures exceed 40 °C); however,
goats in the rDNA/virus group did not experience fever onset
(39.4±0.2 °C) until 5 days post virus inoculation, and only two of four
goats developed small skin lesionswithdiameters of 0.5–1 cm.Moreover,
the fever duration of the rDNA/virus group was 1–2 days shorter than
that of the PBS/virus group. This suggests that DNA prime vaccination
can, to some extent, alleviate the side reactions of live virus vaccination.
Viral challenge results of goats with GTPV-AV40
On DPI 42, goats were challenged with 1000 SID50 standard
virulence strain GTPV-AV40. As expected, goats in the rDNA/virusnant plasmids. Lane 1: BHK-21 mock control; lane 2: negative control pCSm vector; lane
ne 8: pCSm-BAA.
Fig. 3. Speciﬁc anti-GTPV, A27, A33, B5 antibodies of mice (A) and goats (B) after inoculation. The mice and goats were vaccinated at days 0 and 21. Then, sera were collected weekly
after vaccination, and an equal volume of sera from individual mice from the same groups was mixed and tested for the presence of antibodies against GTPV, A27, A33, or B5 by
I-ELISA.
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Table 2
Speciﬁc reaction antibodies and neutralizing antibodies in goat sera.
Groups Speciﬁc reaction antibody titers
at DPI 42
Neutralizing antibody titers
GTPV A27 A33 B5 DPI 14 DPI 35
Group 2.2
(rDNA)
12,800 25,600 25,600 12,800 23, 27, 23, 20;
23.3a
32, 40, 36, 27;
33.8
Group 2.2
(rDNA/virus)
25,600 12,800 12,800 12,800 23, 20, 23, 23;
22.3
51, 45, 51, 55;
50.5
Group 2.3
(PBS/virus)
25,600 12,800 6400 6400 ≤6 55, 40, 40, 38;
43.3
Group 2.4
(control)
≤50 ≤50 ≤50 ≤50 ≤6 ≤6
Equal volume of sera from individual goats from the same groups was mixed and tested
for the presence of speciﬁc reaction antibodies against GTPV, A27, A33, or B5 by I-ELISA.
However, neutralizing antibodies against GTPV were measured one by one using a
modiﬁed neutralization assay.
a Arithmetic mean value.
37M. Zheng et al. / Virology 391 (2009) 33–43vaccinated group or virus group did not develop any clinical signs.
Their behavior and appetite statuses remained normal. As shown in
Figs. 6, 7 and Table 4, on DPC 4, control group goats developed fevers
(mean highest temperature=41.4±0.3 °C) and typical goatpox
clinical symptoms, including stage I skin erythematous papule
(mean diameter=3.3±0.7 cm) formation at the inoculation site.
And fromDPC 7, the behavior and appetite statuses of all goats became
worse (4/4), and multiple stage II skin lesions developed at the non-
inoculation sites. By contrast, goats in the DNA vaccinated group also
showed relatively low fever responses (mean highest tempera-
ture=40.7±0.2) and stage I skin papules with approximately half
the size of the control group goats (mean diameter=1.9±0.4 cm).Fig. 4. Speciﬁc T-lymphocyte proliferation responses of mice (A) and goats (B). Speciﬁc T-l
values higher than 1.5 indicated a positive response.Behaviors and appetites in this group were better than those in the
control group. Moreover, only one goat developed stage II skin lesions.
To further assess the protection efﬁcacy of the two DNA vaccines,
all goats were euthanized and necropsied on DPC 10. No goatpox-
speciﬁc pathological lesions or GTPV-speciﬁc nucleic acids were
found in the rDNA/virus vaccinated group or virus group. Sporadic
nodular enanthems could be found in the lungs (4/4) and
abomasum (1/4) of control goats (Supplement Fig. 4); and 413 bp
GTPV-speciﬁc nucleic acids could also be found by PCR assay in the
lung (4/4), abomasum (2/4), liver (2/4), kidney (2/4), spleen (2/4),
and draining lymph node (2/4) samples. In contrast, sporadic
nodular enanthems were observed in the lungs of only one goat in
the DNA vaccinated group, and GTPV nucleic acids were found in the
lungs of two goats.
Additionally, infectious viruseswere isolated and titrated from skin
lesion samples and PCR positive lung samples of the control group and
DNA vaccinated group. Results showed mean viral titers from skin
lesions and lung samples of the DNA vaccinated group were 104.4
TCID50/g and 105 TCID50/g, respectively, which were 4- and 10-fold
lower than those of the control group (105 TCID50/g and 106 TCID50/g,
respectively).
Thus, DNA vaccination provided partial protection against viral
challenge, and reduced disease severity, viral growth, and dissemina-
tion in hosts. Moreover, DNA prime vaccination alleviated pathogeni-
city of the boosting vaccination using the live vaccine (AV41) on goats,
but did not affect the immunogenicity of live vaccine.
Discussion
Due to the concerns of safety risks and possible vaccination side
effects with attenuated live GPTV vaccines, it is desired to exploreymphocyte proliferation responses of mice and goats were measured by MTT assay. SI
Fig. 5. Speciﬁc IFN-γ responses in vaccinated mice. On DPI 35, antigen-speciﬁc IFN-γ responses of mice were tested by IFN-γ ELISPOT using GTPV-infected-cell-lysate or recombinant
proteins as a simulator, respectively.
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and Wei, 2004; Li et al., 2005; Zhao et al., 2005). Recent studies have
demonstrated the feasibility of developing subunit-based smallpox
vaccines. Both DNA and recombinant protein vaccines using individual
outer membrane proteins of VACV elicited protective antibody
responses in small animal and non-human primate models. Little
data exists on the key protective antigens of capripoxviruses; most
available information is based on the VACV model. In this study, we
attempt to develop an alternative DNA vaccine strategy which
expresses GTPV structural proteins corresponding to the Vaccinia
virus proteins A27, L1, A33, and B5, and investigate their potential as
vaccine candidates against GTPV in goats.
To overcome conventional DNAvaccine low protein expression and
immunogenicity, a new generation of mammal cell expression vector
systems based on the replicon of alphaviruses, including SFV, Sindbis
virus (SINV), and Venezuelan equine encephalitis virus (VEEV), has
recently been developed. These vectors have shown great potential as
gene delivery vehicles for various applications in cancer gene therapy
and vaccine development. For example, Thornburg et al. (2007)
successfully developed a potential anti-cowpox virus vaccine based on
replicon particles of VEEV (VRP). However, the primary technical
drawback of the above-mentioned original alphavirus systems is that
they require production and manipulation of recombinant RNA in
vitro. To address this problem, more recently researchers have made
somemodiﬁcations in original alphavirus expression vectors, resulting
in new DNA-based vectors without the need of in vitro transcription.Fig. 6. Swellings and skin lesions exhibited at the sites of inoculation (A, B) or challenge (C
indicates swelling); B: goat in group 2.3 at 5 days post live vaccine inoculation; C: goat in grou
blue arrow indicate stage I, II skin lesions); F: goat in group 2.2 at 7 days post viral challenge.
to the web version of this article.)These so-called alphavirus replicon-based DNA vaccines, or suicidal
DNA vaccines, simplify the use of alphaviruses in vaccine delivery, but
retain most merits of the alphavirus vector, which include high level
heterologous protein expression and which elicit strong immune
response and apoptosis. Therefore, in this study we introduced an SFV
replicon into the commercial eukaryotic vector pIRESneo, resulting in
a new vector (pCSm) without the need of in vitro transcription, and
then constructed a series of replicative plasmid DNA encoding the
GTPV structural proteins. The resulting plasmids all possessed good
protein expression levels both in vivo and in vitro.
It was previously demonstrated that vaccination with a combina-
tion of IMV and EEV genes (A27, L1, B5, and A33, respectively)
protected animals from challenge more effectively than vaccination
with either gene alone. In almost all reported research to date,
however, only DNA plasmids expressing individual antigens have been
constructed. An obvious drawback is that researchers need to prepare
and inoculate several DNA plasmids, which is laborious and
inefﬁcient. Thus, in addition to DNA plasmid expressing individual
proteins, we also generated two bicistronic expression DNA con-
structs. Currently, many researchers prefer to imitate a co-expression
strategy used by many viruses: to express several proteins as a
polyprotein, then use proteinases to cleavage it into separated
proteins (de Felipe et al., 1999; Furler et al., 2001; Szymczak et al.,
2004). In this study, we used a small peptide of 18 amino acids (2A)
from the foot-and-mouth disease virus (FMDV) to avoid the need for
proteinases to process the polyprotein. FMDV 2A was introduced as a, D, E, and F). A: goat in group 2.2 at 5 days post live vaccine inoculation (black arrow
p 2.1 at 7 days post viral challenge; D, E: control goats at 7 days post viral challenge (red,
(For interpretation of the references to colour in this ﬁgure legend, the reader is referred
Fig. 7. Rectal temperature changes of goats after vaccine inoculation and viral challenge.
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intraribosomal self-processing of polyproteins. As Western blot
analysis revealed, four proteins were correctly expressed and
processed. Considering manipulation convenience and transcription
efﬁciency limitations of the promoter, we did not construct tert-
cistronic in this study, although this would be possible in theory. It
should be noted that un-cleavaged polyproteins were found in the
expression products. Three possible reasons explain this phenom-
enon: (1) affection from the special amino acid sequence or structure
domain at the upstream and downstream of 2A polypeptide in the
polyproteins; (2) high output of protein precursors; or (3) other
infectors, including cell lines. The same phenomenon has been
reported previously by Mattion et al. (1996) and Donnelly et al.
(1997). Taken together, our data provide additional evidence to
support the FMDV 2A sequence as a useful tool to allow for co-
expression of multiple proteins from a single vector.
As expected, the magnitude of GTPV-speciﬁc reaction antibodies
and neutralizing antibodies both in mice and goats followed the order
pCSmAAL+pCSmBAA/virus NVirus ≥ pCSmAAL+pCSmBAA N
pCSmAAL NpCSmL1NpCSmA27 NpCSmBAA NpCSmA33 NpCSmB5,
measured by GTPV-infected-cell-lysate ELISA and viral neutralization
test. It should be noted that the virus neutralization assay used in this
study primarily measures antibodies that neutralize IMV but not EEV;
however, we do observed typical comet-shaped plaque formation in
vTK-EGFP infected LK cells and comet reduction phenomenon when
existing A33- or B5-speciﬁc antibodies. Thus, the weak inhibition
abilities of A33 and B5 sera may be attributed to the presence of anti-
EEV neutralizing antibodies.
It is generally accepted that the immunity to capripox infection is
predominantly cell-mediated. Therefore, in this study we also
evaluate the ability of individual protein to elicit the speciﬁc cellular
response.When simulatedwith individual puriﬁed proteins, we found
that the magnitude of antigen-speciﬁc T-lymphocyte proliferation
responses and IFN-γ responses followed the order A33NB5NA27. It
suggested that EEV proteins (A33 and B5) may play more role than
IMV proteins on cell-mediated response against GTPV.Table 3
Clinical symptom appeared on goats of group 2.2 and 2.3 after live vaccine
immunization.
Groups Days to
onset fever
(no. of animal)
Mean highest
temp±SEM
(°C)
Days to onset
skin lesion
Mean diameter
of lesions±SEM
(cm)
Group 2.2
(rDNA/virus)
5d (2), 6d (2) 39.4±0.2 6d (2), −(2) 0.75±0.25 (2)
Group 2.3
(PBS/virus)
3d (1), 4d (3) 39.9±0.4 4d (4) 1.5±0.5
On DPI 21, goats of group 2.2 and group 2.3 were inoculated intradermally with GTPV-
AV41 and observed for clinical signs of side reactions.
aThe “−” indicates no symptoms.Overall, our results showed that two GTPV IMV proteins (A27 and
L1) and two EEV proteins (B5 and A33) were able to elicit speciﬁc
antibodies and cell-mediated responses in both mice and goats, and
combinations of these four proteins afforded stronger immune
responses. These results are in good agreement with those of other
researchers (Hooper et al., 2003, 2004; Fogg et al., 2004).
Other GTPV structural proteins may also be potential candidate
antigens and should be included in the ﬁnal multivalent DNA-based or
subunit-based GTPV vaccine. For example, Carn et al. (1994)
previously demonstrated that a subunit vaccine made from a GTPV
H3 homolog could also induce a speciﬁc neutralizing antibody, as well
as reduce disease severity and limit local virus spread. This suggests
that H3 is a potential protective antigen of GTPV. However, we did not
examine H3 in this study due to conﬂicting results obtained from
various researches on its VACV counterpart. Results from Pulford et al.
(2004) showed that H3L failed to elicit neutralizing antibody towards
VACV and afforded limited protection (33%), whereas more recently
Davies et al. (2005) found that mice inoculated with puriﬁed H3
protein developed high titer VACV-neutralizing antibodies and all
survived from challenge with one 50% lethal dose VACVNYBOH.
Furthermore, D8, A56, and A36 were also found to potentially serve
as key vaccine components (Pulford et al., 2004).
Compared to one single live virus immunization providing
complete protection against viral challenge, two immunizations of
multivalent formulations comprising two DNA vaccines could only
provide partial protection. Our results parallel previous reports on
mice and non-human primates (Hooper et al., 2003, 2004; Fogg et
al., 2004; Fang et al. 2006; Sakhatskyy et al., 2006). Improving the
immunization strategy and co-expressing cytokine or a co-stimu-
lating factor such as IL-2, IFN, or GM-CSF may enhance the
protective efﬁcacy of DNA vaccines. Particularly, the delivery system
for SFV replicon-based DNA vaccines should be optimized for their
large molecular weight (exceeding 12 kb). Gene guns may serve as
effective administration tools to enhance the immunization effect
of DNA plasmids (Hooper et al., 2007). However, their high-cost
and need for a pre-coat DNA with gold particles make it unsuitable
for clinical veterinary practice. Recently, Chitosan derivative
nanoparticles and trehalose dimycolate were both explored as
potential DNA vaccine carriers and adjuvants (Khatri et al., 2008;
de Paula et al., 2007). Subsequent studies will investigate these
delivery systems and adjuvants, as well as various immunization
doses and frequencies.
In this study we demonstrated that, although GTPV-DNA vaccines
did not afford complete protection to goats from virulent challenge,
priming the vaccination with GTPV-DNA vaccines could signiﬁcantly
reduce the goats' side reactions from boosting vaccinations with live
vaccine (AV41), which include skin lesions at the inoculation site and
fevers. In this context, the DNA primer would immunologically
attenuate the subsequent live vaccine boost. Moreover, our results
showed that, although the rDNA/virus group antibodies increased
Table 4
Clinical symptom appeared on goats after viral challenge.
Group Days to
onset
fever
Mean
highest
temp (°C)
Days to
onset skin
lesion
Mean
diameter of
lesions(cm)
Stage II
lesion or
not
Behave
status,
appetite
Group 2.1
(rDNA)
4d (1),
5d (3)
40.7±0.2 4d (2), 5d
(2)
1.9±0.4 +(1),
−(3)
Worse (1),
bad (3)
Group 2.2
(rDNA/virus)
− − − − − Good (4)
Group 2.3
(PBS/virus)
− − − − − Good (4)
Group 2.4
(Control)
4d 41.4±0.3 4d 3.3±0.7 +(4) Worse (4)
On DPI 42, goats were challenged with 1000 SID50 standard virulence strain GTPV-AV40
and observed for clinical signs of goatpox.
aThe “−” indicates no symptoms.
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responses and cellular responses of goats in this group still reached
the highest levels among all groups on DPI 42. This suggests that
GTPV-DNA vaccines also ultimately enhance the immune effect of the
live virus vaccine. Thus, our study supports the possibility of
improving the safety of the current GTPV vaccine by prime immuniz-
ing with GTPV-DNA vaccines, which enhance immunity prior to
exposure to live GTPV, and thereby lower the risk of potential
complications.
The threat of bioterrorist attacks and natural zoonotic orthopox-
viral (e.g., monkeypox virus) outbreaks provide the impetus for
renewed efforts to develop safe and effective alternative smallpox
vaccines or antiviral drugs. Bowden et al. (2008) recently found that
the pathogenesis and tissue tropism of capripoxvirus infections in
sheep and goats were in marked contrast to those seen with ectro-
melia virus in mice, and instead more closely resembled those of
smallpox and monkeypox. This suggests that goatpox or sheeppox
could be more satisfactory surrogate animal models for smallpox or
monkeypox than traditional rodent models. Therefore, data obtained
in our study could not only facilitate improvement of the current
goatpox vaccination strategy, but also provide valuable guidance to
suitable candidates for evaluation and development of orthopoxvirus
vaccines.
In summary, we showed that SFV replicon-based DNA vaccines
encoding GTPV structural proteins of IMV and EEV, could elicit
strong humoral and cellular responses in mice and goats, provide
partial protection against viral challenge in goats, and reduce
disease symptoms. Additionally, priming vaccination with the
above-mentioned DNA vaccines and boosting with live virus
could improve the efﬁcacy and safety of the current live GTPV vaccine.
Optimal inoculation dosage and frequency, along with rational
adjuvants, will be explored in future studies.
Materials and methods
Viruses and cells
GTPV live attenuated vaccine strain AV41 and standard virulence
strain AV40 were introduced from the China Institute of Veterinary
Drug Control (CIVDC, Beijing) and maintained in secondary bovine
testis (SBT) cell monolayers grown in Eagleminimal essential medium
containing 10% heat-inactivated fetal bovine serum and 1% antibiotics
(100 U/ml penicillin, 100 mg/ml streptomycin). A recombination
GTPV expressing green ﬂuorescent protein, vTK-EGFP, was con-
structed previously by ourselves (unpublished) and was also main-
tained in SBTcells and African greenmonkey kidney (Vero) cells. Baby
hamster kidney (BHK-21) cells were used for transient expression
experiments.Construction of SFV replicon-based expression plasmid pCSm
Adapted from the method illustrated by DiCommo and Bremner
(1998), the plasmid pCSm was built in two stages: (i) Eukaryotic
Expression Vector pIRESneo1 (Clontech, USA) was digested with
EcoRV and XbaI, and was ligated with an 8.0-kb EcoRV–SpeI fragment
from pSFV1 containing the replicon encoding regions and a 26S
promoter of SFV; and (ii) the resulting plasmid, pCS, was cut with
EcoRV and ligated with a 0.28-kb SmaI–EcoRV fragment containing
the ﬁrst part of the SFV genome (generated by ampliﬁcation and
digestion of base pairs 1–279 in pSFV1 with the primer O-SFV1 (SmaI
and EcoRI): 5′-ttcccggggaattcatggcggatgtgtgacat-3′ and reverse pri-
mer O-SFV2: 5′-gtacagcgatgttggtgc-3′). The resulting plasmid, pCSm,
contained a cytomegalovirus intermediate-early promoter/enhancer
and bovine growth hormone poly adenylation-termination signal
upstream and downstream of the SFV replicon and 26S promoter
region, respectively.
Cloning of GTPV genes
The GTPV A27L, L1R, A33R, and B5R orthologous genes were PCR
ampliﬁed fromGTPV-AV41 using Ex-Taq DNA polymerase (Takara Bio.,
Dalian, China) with the primer pairs listed in Table 5. Amplicons were
cloned into the pMD18-T simple vector (Takara Bio., Dalian, China) for
sequencing.
Construction and preparation of GTPV antigen-expressing vectors
The resulting GTPV genes were individually digested by BamHI and
SmaI, and inserted into the expression vector pCSm to generate the
four single expression plasmids pCSm-A27, pCSm-L1, pCSm-A33, and
pCSm-B5.
Meanwhile, a 0.3-kb fragment containing a 2A short peptide
encoding region was ampliﬁed by the primer 2A1 (XbaI): 5′-ctctaga-
ACTTTGAACTTTGATCTACTC-3′ and 2A2 (SmaI): 5′-acccgggGCGCCC-
AATACGCAAAC-3′ from a plasmid pMD-VP12A comprising the VP1
gene and 2A gene of FMDV O/NY00. The 2A fragment was
subsequently inserted into pMD-A27 and pMD-B5 digested similarly
with the BamHI and SmaI, in frame with the A27L or B5R genes. The
resulting plasmids pMD-A272A and pMD-B52A were cut using BglII
(this digestion site was introduced immediately downstream of the
2A gene during the construction of pMD-VP12A) and XbaI, and
inserted by the BamHI–XbaI fragments of L1R and A33R, respectively,
to generate the two expression cassettes A27L-2A-L1R and B5R-2A-
A33R. Finally, two bicistronic expression plasmids, pCSm-AAL and
pCSm-BAA, were obtained by cloning A27L-2A-L1R and B5R-2A-A33R
into the BamHI–SmaI site of pCSm, and sequenced to establish an
intact and representative open reading frame.
Plasmid DNA was prepared in bulk from suitable clones using an
endotoxin-free mega prep kit (Qiagen, Germany) and DNA was
resuspended in sterile PBS. DNA concentrations were determined by
UV spectroscopy.
Expression and puriﬁcation of GTPV A27, A33, and B5 orthologous
proteins
To produce GTPV antigen protein for measuring the levels of
humoral and cellular response in vitro assays, the entire A27L coding
region was PCR ampliﬁed using the primer pairs listed in Table 1, and
cloned into the pET32a vector (Novagen, Germany) in frame with the
5′ puriﬁcation tag sequences (S- and His-Tags). Fragments of the gene
encoding the ectodomain of A33R and B5R were similarly ampliﬁed
and cloned into the pET32a vector.
The recombinant proteins were produced, according to the
manufacturer's instructions, in Escherichia coli BL21 (DE3) and
puriﬁed using TALON IMAC resin (Clontech, USA).
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Plasmid DNA was transfected into BHK-21 cell monolayers (90%
conﬂuent) using Lipofectamine 2000 reagent (Invitrogen, USA)
according to the manufacturer's instructions. After 48 h, the total
cellular lysates were prepared with lysis buffer (10mM Tris–Cl, pH 7.4,
1 mM MgCl2, 0.5% NP40, 20 μg/ml DNase I) and electrophoresed
through an SDS-10% polyacrylamide gel. The proteins were then
transferred onto nitrocellulose membranes (Bio-Rad, USA). Mem-
branes were incubated with anti-GTPV positive sera at a dilution of
1:500. Bound antibody was detected by incubation of the membrane
with rabbit anti-goat IgG antibodies labeled by the alkaline phospha-
tase at a dilution of 1:2000, followed by visualizing with NBT/BCIP
substrates (Promega, USA).
Vaccines and vaccination
Mouse vaccination
Ninety BALB/c mice were separated into nine groups. Group 1.1,
1.2, 1.3, 1.4, 1.5, and 1.6 were vaccinated with 100 μg of pCSm-A27,
pCSm-L1, pCSm-A33, pCSm-B5, pCSm-AAL, and pCSm-BAA in 0.1ml of
phosphate-buffered saline (PBS), respectively. Group 1.7 was vacci-
nated in combination with 100 μg pCSm-AAL and 100 μg pCSm-BAA.
Group 1.8 was injected with 1×105 TCID50 of GTPV-AV41 in 0.1 ml of
PBS, and group 1.9 was injected with 100 μg of pCSm as a control. All
groups were boosted with an equivalent dose at day post-inoculation
(DPI) 21, respectively. Vaccines were injected by inserting a needle
and syringe into the tibialis cranialis muscle of hind legs.
Goat vaccination
Sixteen unvaccinated healthy, seronegative 8-month-old cross-
breeding dairy goats were separated into four groups. Groups 2.1 and
2.2 were vaccinated simultaneously with 500 μg pCSm-AAL and
500 μg pCSm-BAA by intramuscular (IM) inoculation. Group 2.3 was
injected with 1 ml PBS, and group 2.4 was injected intramuscularly
with 500 μg pCSm in 0.5 ml of PBS. On DPI 21, group 2.1 and group 2.4
were boosted with an equivalent dose, respectively; group 2.2 and 2.3
were inoculated intradermally with 0.2 ml of reconstituted commer-
cial live vaccine (Jilin Zhengye Biologicals Co. Ltd., Jilin; containing
1×104 TCID50 live GTPV-AV41 per dose) in the caudal fold, as
described by the manufacturer. The goats were observed daily and
rectal temperature was recorded daily. Animal experiments were
carried out in accordance with the Committee for the Purpose of
Control and Supervision of Experiments on Animals (CPCSEA) guide-
lines for care and handling of experimental animals.Table 5
Primer pairs for cloning of GTPV genes.
Primer pairs were designed basing the GTPV strain Pellor genome (accession no.
AY077835). Primers included the BamHI (AAATCC), SmaI (CCCGGG) and XbaI (TCTAGA)
sites for cloning sequence. And a kozak sequence (CCACCATGG) was inserted into the
upper primer to facilitated expressions of the ORFs. The lower primers contained a TTA
sequence that codiﬁes for termination of protein translation and a sequence encoding
for a poly-histidine sequence at the 3′ side of the termination signal.
aGTPV ORF number adopt lumpy skin disease virus (accession no. AF325528) ORF
number system constructed by Tulman et al. (2001; 2002).
bORF from VACV strain Copenhagen genome (accession no. M35027).Evaluation of the humoral immune response to GTPV
ELISA
Indirect enzyme linked immunosorbent assays (I-ELISA) were
performed on mouse and goat serum to measure the amount of anti-
GTPV virion or viral protein antibodies present in each sample. Brieﬂy,
96-well ﬂat-bottomed plates (Costar, USA) were coated with
formaldehyde-inactivating GTPV-AV41 Vero cell culture lysis, puriﬁed
recombination protein A27, A33, and B5 (200 ng per well),
respectively, in 0.1 M carbonate/bicarbonate buffer (pH 9.6) overnight
at 4 °C. After being blocked with 5% BSA-PBS, plates were incubated
with duplicate 100-fold dilutions of test sera for 1 h at 37 °C.
Peroxidase-conjugated anti-mouse IgG (or anti-goat IgG) conjugate
(Sigma) at 1:4000 dilution was then added for 1 h at 37 °C, followed
by the substrate (0.01% hydrogen peroxide in phosphate/citrate
buffer). The optical density (OD) of the ELISA plate was read at
492 nm. Endpoint titers were determined as the highest dilution with
an absorbance value greater than the mean absorbance value from
negative control plasmid (pCSm)-vaccinated animals plus three
standard deviations.
Neutralization assay
IMV neutralization titers inmice and goat serawere determined by
using a modiﬁed neutralization assay based on observation of green
ﬂuorescent protein. Sera were inactivated at 56 °C for 30 min, after
which 50 μl of each sample or control serumwas added to the well at
the end of each row of a 96-well tissue culture plate, and then diluted
in a 2-fold serial dilution across the plates. 50 μl of 100 TCID50
recombinant GTPV, vTK-EGFP, was subsequently added to each well,
and the plate was vortexed for 1 min. After incubation at 37 °C for
60 min, 100 μl of 105 cells/ml SLT cell in Eagle's MEM containing 2%
fetal bovine serumwas added to each well. After 7 days of incubation
at 37 °C with 5% CO2, plates were observed and the percentage of
infected cells was determined by ﬂuorescence microscope. Endpoint
titers were expressed as the reciprocal of the ﬁnal serum dilution that
resulted in neutralization of the virus activity by 50%.
T-lymphocyte proliferation assay
At 14 days post booster immunization (DPI 35), goat blood was
collected in 5 mM EDTA and used immediately for the isolation of
peripheral blood mononuclear cells (PBMC) using Lymphoprep (TBD,
Tianjin, China). Three mice from each group were killed and
splenocytes were isolated using sterile procedures. The goat PBMCs
and mouse splenocytes were then resuspended in complete culture
medium (RPMI 1640 medium with 10% fetal calf serum). MTT assays
were carried out in triplicate cultures of 200 μl (2×106/ml cells) in 96-
well ﬂat-bottom plates. Brieﬂy, PBMC or splenocyte were stimulated
with 2 μg/ml of recombinant A27, A33 and B5,1:100 inactivated GTPV-
AV41,1 μg/ml Concanavalin A (ConA; Sigma), respectively. Plates were
incubated at 37 °C for 45 h, followed by incubation with MTT for 3 h,
and then 150 μl DMSOwas added to every well to dissolve the deposit.
Absorbance was measured at 570 nm and results were expressed as
stimulation index (SI) (cpm sample/cpm medium alone).
Murine IFN-γ ELISPOT assay
Three mice from each group were sacriﬁced on DPI 35. The
splenocytes were isolated using sterile procedures and resuspended in
RPMI 1640 medium with 10% fetal calf serum. Speciﬁc IFN-γ response
against GTPV was subsequently determined using the mice IFN-γ
ELISPOTassay kit (DakeweBiotechnologyCo. Ltd., Shenzhen,China). 96-
well PVDF-membrane plates (supplied in kit) were coated with
monoclonal antibody to mouse IFN-γ diluted 1/100 in PBS and
incubated overnight at 4 °C. After several washes with PBS, plates
were blocked with complete culture medium for 2 h at room
temperature. Mice splenocytes were added in triplicate at an input cell
number of 1×105 cells per well in 100 μl complete culture medium.
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complete culture medium at a ﬁnal concentration of 10 μg/ml or 1:100,
respectively, and 100 μl dilution were added per well. ConA (5 μg/ml)
wasused asa positive control, and cells resuspended in complete culture
medium only served as a negative control. After an incubation period of
24 h at 37 °C, cell cultureswere discarded and 200 μl of pre-cold distilled
water were added per well followed by incubation at−20 °C for 5 min
and at 4 °C for 5 min. Plates were subsequently washed with PBS and
incubated at 37 °C for 1 h with 100 μl/well of the biotinylated detector
mAb to mouse IFN-γ diluted 1/1000 in PBS supplemented with 1% BSA
(PBS+1% BSA). Plates were washed and 100 μl/well of streptavidin–
alkaline phosphatase conjugate, diluted 1/1000 in PBS+1% BSA, was
added and incubated at 37 °C for 1 h. The plates were thenwashed and
100 μl of AEC substrate solution was added per well. The colorimetric
reaction was terminated after 30 min at room temperature by washing
several times with distilled water. Plates were air-dried and spots were
counted using an automated ELISPOT reader system (Bioreader 4000
PRO, Biosys, Germany). The mean number of spots from triplicate wells
was adjusted to 1×106 splenocytes. ELISPOT data are expressed as
mean±S.D. The antigen-speciﬁc IFN-γ responses were calculated after
subtractionof spots formed in controlmediumwells fromthenumberof
spots formed in response to the corresponding stimulator.
Challenge of goats
To determine the mean skin infective dose (SID50) of GTPV-AV40
in goats, 16 seronegative 8-month-old goats were randomly divided
into four groups (four per group). The stock GTPV-AV40 was diluted
at 10−4, 10−5, 10−6, and 10−7 with PBS. Each goat was injected
intradermally with 1ml of the diluted GTPV solution in the abdominal
area. Clinical symptoms (i.e., skin macules or papule formation on
abdomen, tail, foot, mouth, or nose with body temperature over
41 °C) were observed until 14 days after viral challenge (DPC). The
goats were diagnosed as goatpox positive in the presence of the above
clinical symptoms. The mean skin infective dose that could cause 50%
of the goat to become goatpox positive symptoms was designated as 1
SID50, which was calculated to be 1×106.0/ml.
At 42 days post-initial inoculation, all goats were challenged
intradermally with 1000 SID50 in 0.5 ml in the caudal fold. GTPV-
positive goats were determined according to skin lesion appearance
and body temperature over 41 °C. All goats were kept in separated
stalls within one house. After 10 days of observation, the goats were
euthanatized and necropsied, any pathological lesions were recorded,
and GTPV titers in main organs were determined by virus culture and
PCR (Zheng, 2007).
Statistical analysis
To determine whether immune responses among the groups of
animals were signiﬁcantly different from each other, Student's t-test
analysis was performed using Microsoft Excel software and SPSS
version 10.0.
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